171 related articles for article (PubMed ID: 9548605)
1. Toxicity and morbidity of isolated limb perfusion.
Vrouenraets BC; Klaase JM; Nieweg OE; Kroon BB
Semin Surg Oncol; 1998; 14(3):224-31. PubMed ID: 9548605
[TBL] [Abstract][Full Text] [Related]
2. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
3. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics.
Bartlett DL; Ma G; Alexander HR; Libutti SK; Fraker DL
Cancer; 1997 Dec; 80(11):2084-90. PubMed ID: 9392330
[TBL] [Abstract][Full Text] [Related]
4. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
Vrouenraets BC; Kroon BB; Ogilvie AC; van Geel AN; Nieweg OE; Swaak AJ; Eggermont AM
Ann Surg Oncol; 1999 Jun; 6(4):405-12. PubMed ID: 10379864
[TBL] [Abstract][Full Text] [Related]
5. Pentoxifyllin attenuates the systemic inflammatory response induced during isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan.
Hohenberger P; Latz E; Kettelhack C; Rezaei AH; Schumann R; Schlag PM
Ann Surg Oncol; 2003 Jun; 10(5):562-8. PubMed ID: 12794024
[TBL] [Abstract][Full Text] [Related]
6. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
[TBL] [Abstract][Full Text] [Related]
7. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
[TBL] [Abstract][Full Text] [Related]
8. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs.
Lejeune FJ; Eggermont AM
J Clin Oncol; 2007 Apr; 25(11):1449-50; author reply 1450-1. PubMed ID: 17416870
[No Abstract] [Full Text] [Related]
9. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
Kroon HM; Moncrieff M; Kam PC; Thompson JF
Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
[TBL] [Abstract][Full Text] [Related]
10. [Procalcitonin as marker of systemic inflammatory reaction after isolated extremity perfusion].
Kettelhack C; Hohenberger P; Furchtbar S; Schulze G; Schlag PM
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):399-402. PubMed ID: 14518284
[TBL] [Abstract][Full Text] [Related]
11. [Assessment of regional and systemic toxicity of isolated hyperthermic extremity perfusion with tumor necrosis factor-alpha and melphalan].
Hohenberger P; Haier J; Kettelhack C; Schulze G; Schlag PM
Chirurg; 1997 Sep; 68(9):914-20. PubMed ID: 9410682
[TBL] [Abstract][Full Text] [Related]
12. Systemic toxicity after isolated limb perfusion with melphalan for melanoma.
Sonneveld EJ; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; van Dongen JA; Kroon BB
Eur J Surg Oncol; 1996 Oct; 22(5):521-7. PubMed ID: 8903497
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of isolated limb perfusion in elderly melanoma patients.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Ann Surg Oncol; 2002 Dec; 9(10):968-74. PubMed ID: 12464588
[TBL] [Abstract][Full Text] [Related]
14. Severe acute regional toxicity after normothermic or 'mild' hyperthermic isolated limb perfusion with melphalan for melanoma.
Vrouenraets BC; Kroon BB; Klaase JM; Nieweg OE; van Slooten GW; van Dongen JA
Melanoma Res; 1995 Dec; 5(6):425-31. PubMed ID: 8589617
[TBL] [Abstract][Full Text] [Related]
15. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs.
Thompson JF; Gianoutsos MP
World J Surg; 1992; 16(2):227-33. PubMed ID: 1561803
[TBL] [Abstract][Full Text] [Related]
16. Determinants of acute regional toxicity following isolated limb perfusion for melanoma.
Thompson JF; Eksborg S; Kam PC; Ingvar C; Yau DF; Lai DT; Ramzan I
Melanoma Res; 1996 Jun; 6(3):267-71. PubMed ID: 8819130
[TBL] [Abstract][Full Text] [Related]
17. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM
Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234
[TBL] [Abstract][Full Text] [Related]
18. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan.
Kettelhack C; Hohenberger P; Schulze G; Kilpert B; Schlag PM
Crit Care Med; 2000 Apr; 28(4):1040-6. PubMed ID: 10809279
[TBL] [Abstract][Full Text] [Related]
19. Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan.
Vrouenraets BC; in't Veld GJ; Nieweg OE; van Slooten GW; van Dongen JA; Kroon BB
Eur J Surg Oncol; 1999 Oct; 25(5):503-8. PubMed ID: 10529261
[TBL] [Abstract][Full Text] [Related]
20. Isolated limb perfusion with hyperthermia and chemotherapy: predictive factors for regional toxicity.
Duprat Neto JP; Oliveira F; Bertolli E; Molina AS; Nishinari K; Facure L; Fregnani JH
Clinics (Sao Paulo); 2012; 67(3):237-41. PubMed ID: 22473404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
